FairJourney Biologics
Pedro Carmo serves as a Senior Alliance Manager at FairJourney Biologics since February 2022, where key achievements include exceeding business development objectives and leading the Alliance Management team from 2024. Carmo has extensive experience in business development, focusing on cell line development, drug discovery, and technology transfer, partnering with international biotech and pharmaceutical companies. Carmo has been a Corporate Sponsor Member of The Antibody Society since January 2023. Previous roles include Research Grant Holder at CESAM, where research focused on the toxicity of nanomaterials, and an Undergraduate Researcher at n9ve, studying the environmental effects of heavy metals. Educational qualifications include a Master of Science in Applied Biology and a Bachelor of Science in Biotechnology from Universidade de Aveiro.
FairJourney Biologics
FairJourney Biologics is a privately established company with an outstanding track record of biotech and biopharmaceutical partners (Merus, argenX, BMS, Bayer, among others), offering a range of assets and services on antibody discovery, engineering, production, characterization up to cell line development stages. Our naïve and immune libraries from humans, rodents and llama, together with our know-how and internal technological development allow us to contribute to the pipeline of our partners on complex targets, leading to 14 known antibodies in the clinic. More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects. From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.